Stem Cells Live: Current and Future Trends in Regenerative Medicine

Challenging opening comments by Greg Bonfiglio to initiate this discussion session with a bang. A series of complications have hit the industry in recent days: failure of the Athersys phase two trial, federal reimbursement for wound healing Apligraf (Organogenesis) cut. The question posed is, ‘where is the industry now and are these events predicative of the future?’ Alain Vertes, Managing …

Stem Cells Live: Celebrating the Differences, How the Biotech Culture and Big Pharma Penetrate can Help Each Other Grow the Regen Med Industry

Tim Allsopp of Neusentis, Pfizer joins host Alain Vertes for the first in a series of fireside chats focusing on Big Pharma’s role in the future of regenerative medicine. Pfizer’s strategic decision to invest in regen med stimulated the creation of Neusentis, a unit of Pfizer dedicated to this area. Dr Allsopp also spoke of Pfizer’s active identification of opportunities …

Roslin Cells Announces New Cell Therapy Manufacturing Contract with Pfizer Inc.

Edinburgh, Scotland, May 21, 2014 Roslin Cells announced today that it has signed a contract with Pfizer Inc., acting through Neusentis, a research unit of Pfizer based in Cambridge, UK, to support the manufacture of retinal pigment epithelium (RPE) cells to be used in a cell therapy clinical trial.  This trial will evaluate the therapy for the treatment of patients suffering …